What does atrial fibrillation actually feel like, and why is it dangerous?

Many people with AF feel palpitations (a fluttering or pounding chest), breathlessness, fatigue, light-headedness, or chest tightness. A meaningful minority feel nothing at all and are picked up incidentally on a pulse check or ECG. The danger is not usually the rhythm itself — it is what the disorganised atrial contraction allows to happen. Blood pools in the left atrial appendage, can form clots, and those clots can travel to the brain and cause a stroke. The Heart Foundation estimates AF raises stroke risk about 5-fold compared with people of the same age in normal rhythm. That stroke-prevention conversation is the centre of every AF consultation in Australian general practice.

How does CHA₂DS₂-VA scoring work in Australia and when is anticoagulation recommended?

CHA₂DS₂-VA is a clinical score that estimates yearly stroke risk and helps decide whether oral anticoagulation is appropriate. The Australian version (NHFA/CSANZ 2018) dropped female sex as a risk factor — that is why it is CHA₂DS₂-VA rather than CHA₂DS₂-VASc. Points: heart failure 1, hypertension 1, age 75 or over 2, diabetes 1, prior stroke or TIA 2, vascular disease 1, age 65–74 1. A score of 2 or more usually means oral anticoagulation is recommended. A score of 1 is a shared-decision conversation — annual stroke risk is around 1.3%. A score of 0 means anticoagulation is not recommended for stroke prevention. Bleeding risk (HAS-BLED) is used to identify modifiable risks, not to deny anticoagulation.

Apixaban, rivaroxaban, dabigatran, or warfarin — which one is right?

For most non-valvular AF in Australia, a direct oral anticoagulant (DOAC) is preferred over warfarin. The four DOAC trials (RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE-AF) and the Ruff Lancet meta-analysis showed about a 19% reduction in stroke or systemic embolism and about a 51% reduction in intracranial bleeding compared with warfarin, with similar overall major bleeding. All three Australian DOACs are PBS Authority Required (Streamlined) for non-valvular AF with at least one additional stroke risk factor. Apixaban has dose reduction criteria based on age, weight and creatinine. Dabigatran requires renal monitoring and is avoided if creatinine clearance is under 30. Warfarin remains preferred for mechanical heart valves, moderate-to-severe mitral stenosis, and triple-positive antiphospholipid syndrome. The right answer depends on kidney function, bleeding history, valve status, drug interactions and patient preference.

Rate control or rhythm control — which is better?

Both are reasonable starting points and the choice is increasingly personalised in Australia. Historically, AFFIRM and RACE showed rate and rhythm control were equivalent for survival in older asymptomatic patients, so rate control with a beta-blocker (metoprolol succinate, atenolol, or bisoprolol) became default. The EAST-AFNET 4 trial in 2020 changed that — early rhythm control within a year of diagnosis improved cardiovascular outcomes, particularly in younger, symptomatic, or heart-failure patients. CASTLE-AF showed catheter ablation reduced heart failure hospitalisation and mortality in AF with reduced ejection fraction. The CSANZ 2023 expert position now supports catheter ablation as a Class I option in symptomatic paroxysmal AF refractory to one antiarrhythmic, and as first-line for selected persistent AF and AF with heart failure. For most stable older patients without bothersome symptoms, lenient rate control (resting heart rate under 110) remains appropriate.

What lifestyle changes actually reduce AF burden?

Four interventions have the strongest Australian evidence. Weight loss of 10% or more (LEGACY trial) substantially reduces AF burden and recurrence after ablation. Reducing alcohol — the Voskoboinik NEJM 2020 abstinence trial showed clear reductions in AF episodes in moderate drinkers who stopped drinking. Treating obstructive sleep apnoea — when CPAP is used effectively, AF recurrence after cardioversion or ablation is roughly halved. Treating hypertension to a target of under 130/80. Moderate aerobic exercise (about 150 minutes per week) is beneficial, though very high-volume endurance exercise (more than 20 hours per week) paradoxically raises AF risk in some athletes. Moderate caffeine intake is not a meaningful AF trigger in current evidence — addressing the anxiety around palpitations is often more useful than removing coffee.

What about Apple Watch, KardiaMobile and other consumer wearables that flag AF?

Consumer single-lead devices (Apple Watch, KardiaMobile, Fitbit, Samsung Galaxy Watch) can detect irregular pulse patterns suggestive of AF and have improved substantially in accuracy. They are useful for opportunistic screening, especially in patients with intermittent palpitations that are hard to capture on an in-clinic ECG. The Australian general-practice position: a wearable AF notification is a starting point, not a diagnosis. The standard is still a 12-lead ECG or a physician-interpreted rhythm strip of at least 30 seconds. If a wearable flags AF, the next step is a clinic ECG and a structured AF workup — bloods including thyroid function, an echocardiogram, and consideration of Holter or patch monitoring if episodes are paroxysmal. Do not start anticoagulation on a wearable alert alone.

Atrial fibrillation

Atrial fibrillation: stroke prevention first, symptom control second

By Dr HB Lo, FACRRM Reviewed 18 May 2026 13 min read

Atrial fibrillation (AF) is an irregularly irregular rhythm where the atria quiver instead of contracting. About 2% of Australian adults and 10% over age 75 have it.

Stroke prevention is the clinical priority — AF raises stroke risk ~5-fold untreated. Anticoagulation eligibility uses CHA₂DS₂-VA (2018 NHFA/CSANZ removed the sex variable). DOACs (apixaban, rivaroxaban, dabigatran) are preferred over warfarin for most non-valvular AF and are PBS-subsidised.

Symptom control: rate control for most, rhythm control (antiarrhythmic or catheter ablation) for symptomatic, younger, or recent-onset cases. Modifiable drivers — BP, weight, sleep apnoea, alcohol — reduce AF burden.

What atrial fibrillation actually is

Atrial fibrillation is the most common sustained heart rhythm disturbance seen in Australian general practice. The top chambers of the heart (the atria) lose their coordinated contraction and quiver chaotically instead of beating in rhythm. The pulse becomes irregularly irregular — no predictable pattern, varying intervals between beats, often varying force as well. Some people describe a fluttering or thumping in the chest, breathlessness on stairs that did not used to be there, or a sense of fatigue that does not lift. Others feel nothing at all and are diagnosed incidentally on a routine pulse check or ECG.

The reason general practitioners take AF seriously is not usually the rhythm itself — it is the stroke. When the atria stop contracting properly, blood can pool in the left atrial appendage, form a clot, and travel to the brain. The Heart Foundation and the NHFA/CSANZ 2018 Australian guideline estimate AF raises stroke risk roughly 5-fold compared with people of the same age in normal rhythm. About 2% of Australian adults — roughly 500,000 people — have AF, and the prevalence rises to about 10% in those aged 75 and over, with lifetime risk around one in four (AIHW). Aboriginal and Torres Strait Islander adults develop AF earlier and have higher complication rates. Up to 30% of AF in general practice is undiagnosed, which is why the RACGP Red Book recommends an opportunistic pulse check at every consultation for adults aged 65 and over.

AF is described by pattern, because pattern changes treatment. Paroxysmal AF terminates on its own within seven days. Persistent AF lasts longer than seven days and usually needs cardioversion to restore rhythm. Long-standing persistent AF has been continuous for more than a year. Permanent AF is when patient and clinician have together accepted the rhythm and stopped trying to restore sinus. All four patterns carry the same stroke risk and the same anticoagulation conversation.

A. Core clinical — the AU primary-care framework

How AF is diagnosed

The NHFA/CSANZ 2018 guideline sets the diagnostic standard: AF on ECG shows absent P waves and an irregular fibrillatory baseline (best seen in lead V1 or II), with an irregularly irregular ventricular response. A single 12-lead ECG or any rhythm strip of at least 30 seconds meets criteria. In Australian general practice the in-clinic 12-lead ECG is the workhorse, billable as MBS item 11707 (Heart Foundation).

The clinical workup beyond the ECG:

History — palpitations, breathlessness, fatigue, light-headedness, syncope, chest tightness; AF triggers (alcohol binge — “holiday heart”, caffeine, sepsis, post-operative state, thyroid disease, sleep apnoea); cardiovascular risk factors; bleeding history; falls.
Examination — irregularly irregular pulse, blood pressure in both arms, signs of heart failure (jugular venous pressure, basal crackles, oedema), thyroid signs, body mass index and neck circumference for sleep apnoea screening.
First-line investigations — full blood count, urea and electrolytes, liver function, thyroid stimulating hormone, HbA1c, lipids, BNP or NT-proBNP if heart failure is suspected.
Transthoracic echocardiogram — assesses left ventricular function, atrial size, valve disease, and structural cause.
Sleep study if obstructive sleep apnoea features are present — loud snoring, witnessed apnoeas, daytime somnolence, body mass index 30 or over.
Holter or patch monitor for suspected paroxysmal AF that does not show on a clinic ECG.

A wearable single-lead device (Apple Watch, KardiaMobile, Fitbit) flagging “AF detected” is not a diagnosis on its own — the NHFA/CSANZ position is to confirm with a physician-interpreted 12-lead ECG before initiating treatment.

The ABC framework

The 2018 Australian guideline and the aligned ESC 2024 update describe AF management as three integrated streams that run in parallel:

A — Anticoagulation for stroke prevention.
B — Better symptom control (rate or rhythm).
C — Cardiovascular risk and comorbidity management.

A is non-negotiable for anyone meeting the criteria. B is where the personalised conversation happens. C is the part patients often underestimate but where the largest reductions in AF burden actually live.

B. Stroke prevention — CHA₂DS₂-VA scoring and anticoagulation evidence

Scoring stroke risk the Australian way

In 2018 the NHFA/CSANZ AF guideline dropped female sex from the older CHA₂DS₂-VASc score, renaming the Australian version CHA₂DS₂-VA. The reasoning was that female sex on its own (without other risk factors) inflated risk estimates without changing management. The international ESC 2024 guideline then aligned with the same change. Points:

Letter	Variable	Points
C	Heart failure / left ventricular dysfunction	1
H	Hypertension	1
A₂	Age 75 or over	2
D	Diabetes mellitus	1
S₂	Prior stroke, TIA, or thromboembolism	2
V	Vascular disease (prior MI, peripheral arterial disease, aortic plaque)	1
A	Age 65–74	1

A score of 2 or more → oral anticoagulation recommended. A score of 1 → shared decision with the patient (annual stroke risk around 1.3%). A score of 0 → no antithrombotic for stroke prevention.

The companion score, HAS-BLED, estimates bleeding risk and includes uncontrolled hypertension, abnormal renal or liver function, prior stroke, prior major bleed, labile INR, age over 65, and concurrent drugs (NSAIDs, antiplatelets) or alcohol. A high HAS-BLED score is not a reason to withhold anticoagulation — it is a flag to modify what is modifiable (control blood pressure, stop NSAIDs, reduce alcohol).

DOAC vs warfarin — what the trials showed

Four large randomised trials compared direct oral anticoagulants (DOACs) against warfarin in non-valvular AF: RE-LY (dabigatran), ROCKET-AF (rivaroxaban), ARISTOTLE (apixaban), and ENGAGE-AF (edoxaban — not subsidised in Australia for AF). The Ruff Lancet 2014 meta-analysis of all four showed:

19% relative reduction in stroke or systemic embolism
51% relative reduction in intracranial haemorrhage
Similar overall major bleeding
No requirement for INR monitoring

That evidence is why Australian Prescriber, eTG, and NPS MedicineWise all position DOACs as first-line for non-valvular AF in Australia.

Standard adult doses per AMH:

Agent	Standard dose	Reduced dose criteria
Apixaban	5 mg twice daily	2.5 mg twice daily if 2 or more of: age 80+, weight 60 kg or less, creatinine 133 μmol/L or more
Rivaroxaban	20 mg daily with food	15 mg daily if creatinine clearance 15–49 mL/min
Dabigatran	150 mg twice daily	110 mg twice daily if age 75+, CrCl 30–50, or bleeding risk; avoid if CrCl under 30
Warfarin	INR target 2–3	First-line for mechanical valves, moderate-to-severe mitral stenosis, triple-positive antiphospholipid syndrome

Warfarin remains preferred when DOACs have not been shown safe — mechanical heart valves (RE-ALIGN trial), moderate-to-severe mitral stenosis, and triple-positive antiphospholipid syndrome (TRAPS). Renal function should be rechecked every 6–12 months on a DOAC, more often if the eGFR is borderline. Major drug interactions matter — strong CYP3A4 or P-glycoprotein inhibitors (azoles, ritonavir, ciclosporin) raise DOAC levels; rifampicin, carbamazepine, phenytoin and St John’s wort lower them.

Reversal: idarucizumab for dabigatran, andexanet alfa for factor-Xa inhibitors (Australian availability is changing — check current TGA and PBS status), and 4-factor prothrombin complex concentrate with supportive care for life-threatening bleeding.

C. Rate control vs rhythm control — recent evidence

Rate control — the default for most

For most patients, particularly older or asymptomatic ones, rate control with a beta-blocker is the standard first step (eTG, AMH):

Metoprolol succinate 25–100 mg twice daily, bisoprolol 2.5–10 mg daily, or atenolol 25–100 mg daily.
Non-dihydropyridine calcium channel blockers — diltiazem 120–360 mg or verapamil 80–240 mg — are alternatives when a beta-blocker is contraindicated and ejection fraction is preserved (avoid in heart failure with reduced ejection fraction).
Digoxin is now a narrower second-line agent, mostly reserved for elderly sedentary patients or as add-on in heart failure with reduced ejection fraction. Target serum level 0.5–0.9 nmol/L; caution with worsening renal function.

The target heart rate is debated. The RACE II trial (NEJM 2010) showed that lenient rate control (resting heart rate under 110) was non-inferior to strict control (under 80) for major cardiovascular outcomes. So for most asymptomatic patients, lenient is appropriate. Strict control is reserved for patients with persistent symptoms or tachycardia-induced cardiomyopathy.

Rhythm control — when to push for sinus rhythm

The case for rhythm control has strengthened in recent years. EAST-AFNET 4 (NEJM 2020) showed that early rhythm control within the first year of diagnosis improved cardiovascular outcomes (a composite of cardiovascular death, stroke, and hospitalisation) compared with usual care. CASTLE-AF (NEJM 2018) showed that catheter ablation in AF with heart failure and reduced ejection fraction reduced hospitalisation and mortality. CABANA (JAMA 2019) was neutral on its primary endpoint but favoured ablation on quality-of-life and AF-recurrence outcomes.

Rhythm control is reasonable for:

Patients still symptomatic on adequate rate control
Younger patients and those with recent-onset AF
AF with reduced ejection fraction heart failure
Tachycardia-induced cardiomyopathy

How rhythm is restored:

Electrical cardioversion — synchronised DC shock, biphasic 200 J; requires at least 3 weeks of therapeutic anticoagulation pre-procedure (or transoesophageal echo to exclude atrial thrombus), and at least 4 weeks post regardless of stroke risk score.
Pharmacological cardioversion — flecainide (200–300 mg orally as “pill in pocket” for selected paroxysmal AF without structural heart disease — specialist-initiated) or intravenous amiodarone.

Maintenance antiarrhythmic medication is usually specialist-initiated and includes flecainide (must be combined with a rate-controlling agent to prevent 1:1 atrial flutter conduction), sotalol (with QTc monitoring; not for heart failure), amiodarone (most effective but multi-organ toxicity — thyroid, lung, liver, eye — so reserved), and dronedarone (alternative without permanent AF or heart failure; ATHENA NEJM 2009).

Catheter ablation has moved up the algorithm. The CSANZ 2023 expert position statement makes it Class I for symptomatic paroxysmal AF refractory to or intolerant of one antiarrhythmic drug, Class I as first-line in symptomatic persistent AF without major recurrence risk factors, and Class I in AF with heart failure with reduced ejection fraction. STOP-AF First and EARLY-AF supported first-line ablation as superior to antiarrhythmic drug therapy for paroxysmal AF.

When to refer to cardiology

Urgent referral or emergency department: haemodynamic instability, suspected pre-excitation (AF in Wolff-Parkinson-White — broad, irregular, very rapid rhythm where AV nodal blockers must be avoided), new stroke or TIA, syncope, acute pulmonary oedema.

Same-week cardiology: new AF diagnosis especially under 65, structural heart disease, pregnancy with AF, or anticoagulation contraindication where left atrial appendage occlusion may be considered.

Routine: symptomatic on rate control, AF with heart failure for ablation consideration, antiarrhythmic monitoring.

D. Australian operations

The NHFA/CSANZ 2018 guideline is the AU primary tier for diagnosis and stroke prevention, and the CSANZ 2023 expert position statement is current for ablation. The ESC 2024 guideline aligns closely and is used internationally.

PBS subsidisation (Authority Required — Streamlined):

Apixaban has been PBS-listed for stroke prevention in non-valvular AF with at least one additional stroke risk factor since 2014.
Rivaroxaban and dabigatran are listed under equivalent criteria. Streamlined codes apply — verify on the day of prescribing (NPS DOAC listings).
Warfarin — PBS general schedule.
Beta-blockers (metoprolol succinate, bisoprolol, atenolol, carvedilol, nebivolol) — general schedule.
Diltiazem, verapamil, digoxin, flecainide, sotalol, amiodarone — general schedule.
Dronedarone — Authority Required for symptomatic paroxysmal or persistent AF without heart failure or permanent AF.

(MBS / PBS items verified 2026-05-18 via WebSearch — workspace egress to mbsonline.gov.au + pbs.gov.au still blocked; spot-check confirms current.)

MBS items in routine AF general practice care:

12-lead ECG in clinic — item 11707 (replaced 11700/11701/11702 in August 2020).
Heart Health Check items 699 and telehealth 177.
GP Chronic Condition Management Plans — items 965 and 967 (AF qualifies as chronic).
INR pathology for patients on warfarin — item 66819.
Specialist-referred transthoracic echocardiogram — items 55126 and 55130.
Practice nurse item 10997.
Aboriginal and Torres Strait Islander Health Assessment — item 715.

Driving — per Austroads Assessing Fitness to Drive, AF with adequate rate control and no syncope is usually compatible with a private licence. Commercial licence requires stable controlled rhythm without syncope. After cardioversion, typically 24 hours off driving; after catheter ablation, two weeks off for private and four weeks for commercial.

E. Special populations

Aboriginal and Torres Strait Islander adults. AF develops earlier and complication rates are higher; the condition is often under-recognised in general practice (AIHW). Opportunistic pulse checks, the ATSI Health Assessment item 715, and culturally safe care via Aboriginal Community Controlled Health Organisations are core.

Older adults and frailty. Bleeding risk rises with age, but so does stroke risk — anticoagulation is rarely withheld on age alone. The Australian Prescriber review supports apixaban with appropriate dose reduction in this group. Falls history alone is generally not a reason to withhold anticoagulation — the absolute reduction in stroke usually outweighs increased haemorrhage risk.

Chronic kidney disease. Dose adjustment is essential — apixaban reduces with age, weight, and creatinine; rivaroxaban reduces with creatinine clearance 15–49; dabigatran is avoided if creatinine clearance is under 30. Recheck eGFR every 6 months, more often if borderline.

Pregnancy. Warfarin is teratogenic in the first trimester; DOACs cross the placenta and lack safety data. Low molecular weight heparin is the AU preference, with specialist obstetric and cardiology co-management.

Athletes and “vagally-mediated” AF. Lifetime high-volume endurance exercise (over 20 hours per week) is associated with paradoxically higher AF risk in middle-aged endurance athletes. Moderating training volume can reduce burden; ablation outcomes are generally good in this group.

When to escalate / cardiology referral

Call 000 or go straight to ED for any of these:

New chest pain with the AF episode
Severe breathlessness, light-headedness, or fainting
Focal weakness, slurred speech, sudden visual change, or face droop — possible stroke
New irregular pulse over 200 — possible pre-excitation
Severe headache, sudden bruising, or blood in stool or urine while on an anticoagulant

Same-week GP review:

A wearable device flagging AF that you have not yet confirmed
Increasing palpitations, fatigue, or breathlessness with known AF
Missed anticoagulant doses
Planning surgery, dental extraction, or a procedure while on anticoagulation

Routine cardiology referral:

Newly diagnosed AF for echocardiogram and ablation discussion
Symptomatic on rate control
AF with heart failure
Considering rhythm control or “pill in pocket” strategy

What this article is and is not

This is general health information drawn from current Australian primary-care guidelines — the NHFA/CSANZ 2018 AF guideline, the CSANZ 2023 ablation expert position, Therapeutic Guidelines (eTG), Australian Medicines Handbook, Australian Prescriber, NPS MedicineWise, and the RACGP Red Book — supplemented by the major AF trials. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about specific treatment, including the choice and dose of anticoagulant, rate-control agents, rhythm-control strategy, or referral for ablation, are made with your own GP and treating clinicians.

For Australian consumer-friendly sources: HealthDirect — Atrial fibrillation, Heart Foundation — Atrial fibrillation, Better Health Channel — Atrial fibrillation, Stroke Foundation — AF stroke prevention.

For suspected stroke (face droop, arm weakness, speech changes, time to call): the F.A.S.T. message from Stroke Foundation — call 000 immediately.

Sources cited

Frequently asked questions

What does atrial fibrillation actually feel like, and why is it dangerous?

Many people with AF feel palpitations (a fluttering or pounding chest), breathlessness, fatigue, light-headedness, or chest tightness. A meaningful minority feel nothing at all and are picked up incidentally on a pulse check or ECG. The danger is not usually the rhythm itself — it is what the disorganised atrial contraction allows to happen. Blood pools in the left atrial appendage, can form clots, and those clots can travel to the brain and cause a stroke. The Heart Foundation estimates AF raises stroke risk about 5-fold compared with people of the same age in normal rhythm. That stroke-prevention conversation is the centre of every AF consultation in Australian general practice.
How does CHA₂DS₂-VA scoring work in Australia and when is anticoagulation recommended?

CHA₂DS₂-VA is a clinical score that estimates yearly stroke risk and helps decide whether oral anticoagulation is appropriate. The Australian version (NHFA/CSANZ 2018) dropped female sex as a risk factor — that is why it is CHA₂DS₂-VA rather than CHA₂DS₂-VASc. Points: heart failure 1, hypertension 1, age 75 or over 2, diabetes 1, prior stroke or TIA 2, vascular disease 1, age 65–74 1. A score of 2 or more usually means oral anticoagulation is recommended. A score of 1 is a shared-decision conversation — annual stroke risk is around 1.3%. A score of 0 means anticoagulation is not recommended for stroke prevention. Bleeding risk (HAS-BLED) is used to identify modifiable risks, not to deny anticoagulation.
Apixaban, rivaroxaban, dabigatran, or warfarin — which one is right?

For most non-valvular AF in Australia, a direct oral anticoagulant (DOAC) is preferred over warfarin. The four DOAC trials (RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE-AF) and the Ruff Lancet meta-analysis showed about a 19% reduction in stroke or systemic embolism and about a 51% reduction in intracranial bleeding compared with warfarin, with similar overall major bleeding. All three Australian DOACs are PBS Authority Required (Streamlined) for non-valvular AF with at least one additional stroke risk factor. Apixaban has dose reduction criteria based on age, weight and creatinine. Dabigatran requires renal monitoring and is avoided if creatinine clearance is under 30. Warfarin remains preferred for mechanical heart valves, moderate-to-severe mitral stenosis, and triple-positive antiphospholipid syndrome. The right answer depends on kidney function, bleeding history, valve status, drug interactions and patient preference.
Rate control or rhythm control — which is better?

Both are reasonable starting points and the choice is increasingly personalised in Australia. Historically, AFFIRM and RACE showed rate and rhythm control were equivalent for survival in older asymptomatic patients, so rate control with a beta-blocker (metoprolol succinate, atenolol, or bisoprolol) became default. The EAST-AFNET 4 trial in 2020 changed that — early rhythm control within a year of diagnosis improved cardiovascular outcomes, particularly in younger, symptomatic, or heart-failure patients. CASTLE-AF showed catheter ablation reduced heart failure hospitalisation and mortality in AF with reduced ejection fraction. The CSANZ 2023 expert position now supports catheter ablation as a Class I option in symptomatic paroxysmal AF refractory to one antiarrhythmic, and as first-line for selected persistent AF and AF with heart failure. For most stable older patients without bothersome symptoms, lenient rate control (resting heart rate under 110) remains appropriate.
What lifestyle changes actually reduce AF burden?

Four interventions have the strongest Australian evidence. Weight loss of 10% or more (LEGACY trial) substantially reduces AF burden and recurrence after ablation. Reducing alcohol — the Voskoboinik NEJM 2020 abstinence trial showed clear reductions in AF episodes in moderate drinkers who stopped drinking. Treating obstructive sleep apnoea — when CPAP is used effectively, AF recurrence after cardioversion or ablation is roughly halved. Treating hypertension to a target of under 130/80. Moderate aerobic exercise (about 150 minutes per week) is beneficial, though very high-volume endurance exercise (more than 20 hours per week) paradoxically raises AF risk in some athletes. Moderate caffeine intake is not a meaningful AF trigger in current evidence — addressing the anxiety around palpitations is often more useful than removing coffee.
What about Apple Watch, KardiaMobile and other consumer wearables that flag AF?

Consumer single-lead devices (Apple Watch, KardiaMobile, Fitbit, Samsung Galaxy Watch) can detect irregular pulse patterns suggestive of AF and have improved substantially in accuracy. They are useful for opportunistic screening, especially in patients with intermittent palpitations that are hard to capture on an in-clinic ECG. The Australian general-practice position: a wearable AF notification is a starting point, not a diagnosis. The standard is still a 12-lead ECG or a physician-interpreted rhythm strip of at least 30 seconds. If a wearable flags AF, the next step is a clinic ECG and a structured AF workup — bloods including thyroid function, an echocardiogram, and consideration of Holter or patch monitoring if episodes are paroxysmal. Do not start anticoagulation on a wearable alert alone.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.